Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the formation of a Scientific Advisory Board comprised of industry leaders in neurology and psychiatry, chaired by James E. Galvin, MD, MPH.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Diabetes turns out to be one of the factors in the development of Alzheimer's disease. One of the main features of diabetes - hyperglycemia - is responsible for alzheimer's-like changes.

A study by neuroscientists at the University of Nevada Las Vegas (UNLV) showed that chronic hyperglycemia also impairs memory.

University of Nevada, Las Vegas (UNLV) neuroscientists report on study findings purportedly strengthening the link between Type 2 diabetes and Alzheimer’s disease.

A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.

A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.

A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.

A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.

Neuroscientists show that chronic hyperglycemia affects fundamental aspects of memory.

In a new study from the University of Nevada, Las Vegas, researchers confirmed the link between type 2 diabetes and Alzheimer’s disease.

Eisai and Biogen announced that Eisai has initiated a rolling submission to the US Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company’s investigational anti-amyloid beta (Aß) protofibril antibody, for the treatment of early Alzheimer’s disease (early AD).